News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Forest Laboratories, Inc., Gedeon Richter Ltd. May Do Additional Phase II Cariprazine Trial; Drug Misses Overall Goal
August 30, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Bloomberg -- Gedeon Richter Nyrt., Hungary’s largest drugmaker, said that the Phase II clinical trial of Cariprazine for bipolar depression produced no “statistically significant” result compared with placebo treatment.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
MORE ON THIS TOPIC
Clinical Research
Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix
December 9, 2025
·
3 min read
·
Annalee Armstrong
Obesity
Structure Stock Soars as Oral GLP-1 Generates ‘Highly Competitive’ Weight Loss
December 9, 2025
·
2 min read
·
Tristan Manalac
Infectious disease
Assembly’s Antivirals Show ‘Striking’ Drop in Lesions, Viral Shedding in Early Genital Herpes Study
December 9, 2025
·
2 min read
·
Tristan Manalac
Policy
As FDA Deploys Agentic AI, Pharma Begins Testing the Next Frontier of Intelligent Automation
December 8, 2025
·
3 min read
·
Jennifer Smith-Parker
